Affimed N.V. Affimed is a NASDAQ-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. | Societal CDMO Recro Gainesville (also known as Recro Pharma) is a clinical-stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post-operative pain. | |||
Founding Date | Founding Date 1948 | Founding Date 2000 | Founding Date 1996 | Founding Date 2006 |
Type | Type Subsidiary | Type Public | Type Subsidiary | Type Public |
Tags | ||||
Locations | Locations Heidelberg, DE HQ | Locations Saint-Quentin-Fallavier, FR HQ | Locations Gainesville, US HQ Gainesville, US San Diego, US | |
Employees | Employees 640 | Employees 76 | Employees 2081% increase | Employees 21316% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 67.3 m | Valuation ($) N/A | Valuation ($) 116.1 m |
Financial | ||||
Revenue (est.) | Revenue (est.) £731.3m (FY, 2019) | Revenue (est.) €8.3m (FY, 2023) | Revenue (est.) £95.9m (FY, 2015) | Revenue (est.) $94.6m (FY, 2023) |
Cost of goods | Cost of goods £221m (FY, 2019) | Cost of goods N/A | Cost of goods £43.1m (FY, 2015) | Cost of goods $76.5m (FY, 2023) |
Gross profit | Gross profit £510.3m (FY, 2019) | Gross profit €13m (FY, 2023) | Gross profit £52.8m (FY, 2015) | Gross profit N/A |
Net income | Net income £88.3m (FY, 2019) | Net income (€105.9m) (FY, 2023) | Net income N/A | Net income ($13.3m) (FY, 2023) |